Stockscreener 앱 받기
9.02
8.02%
0.67
전일 마감가:
$8.35
열려 있는:
$8.95
하루 거래량:
23,776
Relative Volume:
1.94
시가총액:
$76.55M
수익:
-
순이익/손실:
$-53.45M
주가수익비율:
-0.4155
EPS:
-21.71
순현금흐름:
$-31.81M
1주 성능:
-9.71%
1개월 성능:
+17.91%
6개월 성능:
-35.11%
1년 성능:
-9.26%
1일 변동 폭
$8.50
$9.50
1주일 범위
$8.00
$9.95
52주 변동 폭
$5.90
$18.17
Surrozen Inc Stock (SRZN) Company Profile
명칭
Surrozen Inc
전화
650-475-2820
주소
171 OYSTER POINT BLVD, SOUTH SAN FRANCISCO
SRZN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRZN
Surrozen Inc
|
9.02 | 76.55M | 0 | -53.45M | -31.81M | -21.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Surrozen Inc Stock (SRZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-30 | 개시 | H.C. Wainwright | Buy |
| 2025-01-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-11 | 개시 | BofA Securities | Buy |
| 2021-09-15 | 개시 | Guggenheim | Buy |
| 2021-09-07 | 개시 | Stifel | Buy |
Surrozen Inc 주식(SRZN)의 최신 뉴스
Surrozen (SRZN) Files for $150 Million Mixed Securities Offering - GuruFocus
Surrozen (SRZN) Files for $150 Million Mixed Securities Offering | SRZN Stock News - GuruFocus
Surrozen Inc Files For Mixed Shelf Of Up To $150 MillionSEC Filing - marketscreener.com
(SRZN) Proactive Strategies - news.stocktradersdaily.com
Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround - Yahoo Finance
Surrozen Holds Successful 2025 Annual Stockholders Meeting - TipRanks
Surrozen secures patent for tissue repair technology By Investing.com - Investing.com Nigeria
Surrozen granted patent from USPTO directed to antibody-based molecules - TipRanks
Surrozen (SRZN) Secures New U.S. Patent for Innovative SWAPTM Te - GuruFocus
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway - The Manila Times
Surrozen secures patent for tissue repair technology - Investing.com
Breakthrough Patent: Surrozen's New Wnt Technology Could Transform Tissue Repair Therapeutics - Stock Titan
Surrozen’s (SRZN) Buy Rating Reaffirmed at HC Wainwright - Defense World
Surrozen (SRZN) Receives Continued "Buy" Rating from HC Wainwright | SRZN Stock News - GuruFocus
Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Surrozen, Inc. Reports Q1 2025 Financial Results - TipRanks
Surrozen, Inc. Reports First Quarter 2025 Financial Results and Business Update Focused on Ophthalmology Pipeline - Nasdaq
CyberCatch Announces Cybersecurity Solution To Protect Thousands of Drinking Water Systems in U.S. that EPA OIG Report Reveals are at Risk of Cyber Attack with One-Day Disruption Cost of $43.5 Billion - The Globe and Mail
BestGrowthStocks.Com Issues a Comprehensive Analysis of Richtech Robotics - The Globe and Mail
Surrozen’s SZN-8141 ameliorates retinopathy in murine models - BioWorld MedTech
Trend Tracker for (SRZN) - news.stocktradersdaily.com
Surrozen files to sell 5.21M shares of common stock for holders - MSN
When (SRZN) Moves Investors should Listen - news.stocktradersdaily.com
Finance Watch: As Stocks Tumble, Offerings Slow, Financial Alternatives Rise - insights.citeline.com
Surrozen’s Strategic Shift to Ophthalmology and Wnt Pathway Innovations Justify Buy Rating - TipRanks
Insiders Are Loving These 5 Tech and Biotech Stocks - 24/7 Wall St.
Surrozen (SRZN) to Release Earnings on Wednesday - Defense World
Surrozen Focuses on Ophthalmology Amid Financial Challenges - TipRanks
Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates - The Manila Times
Surrozen Lands Massive $175M Deal: What This Means for Its Eye Disease Pipeline - Stock Titan
Friday’s Insider Moves: Major Buys in Insurance and Biotech, Sells in Energy - Investing.com Australia
Surrozen sees $11.9 million in stock purchases by Column Group - Investing.com UK
Surrozen Secures $76.4M in Private Placement Deal - TipRanks
Surrozen drops hepatitis drug after Phase I flop - Yahoo
Surrozen shifts focus to eye disease treatments, secures $175M funding - Investing.com India
Surrozen Secures $175Mln In Oversubscribed Private Placement To Advance Ophthalmology Pipeline - Nasdaq
Surrozen to Raise Up to $175 Million in Private Placement; Fine-Tunes Ophthalmology Clinical Programs - MarketScreener
Surrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fund - Endpoints News
Surrozen shifts focus to eye disease treatments, secures $175M funding By Investing.com - Investing.com South Africa
Surrozen, Inc. Prioritizes Ophthalmology Pipeline with $175 Million Financing and Discontinues SZN-043 Development - Nasdaq
Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases - The Manila Times
Major Pivot: Surrozen Lands $175M to Develop Breakthrough Eye Disease Treatments - Stock Titan
(SRZN) Trading Advice - Stock Traders Daily
Reviewing Surrozen (NASDAQ:SRZN) & Tenaya Therapeutics (NASDAQ:TNYA) - Defense World
Wnt efforts condensing at Dewpoint, Surrozen, more - BioWorld MedTech
(SRZN) On The My Stocks Page - Stock Traders Daily
Week Ahead (Sep.13- 17): FDA Decision, Data Readouts (CALT, ASLN, LIFE…) - RTTNews
Better Warren Buffett Stock: Nu Holdings vs. Bank of America - The Globe and Mail
(SRZN) Trading Signals - Stock Traders Daily
H.C. Wainwright sets $32 target on Surrozen stock with Buy rating - MSN
MicroStrategy Is Rebranding to ‘Strategy.’ Should You Buy, Sell, or Hold MSTR Stock? - The Globe and Mail
Surrozen Inc (SRZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Surrozen Inc 주식 (SRZN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Li Yang | Exec. Vice President, Research |
Jan 03 '25 |
Sale |
17.37 |
843 |
14,643 |
13,345 |
| Williams Charles O | CFO and COO |
Jan 03 '25 |
Sale |
17.37 |
1,181 |
20,514 |
8,982 |
1.11%
1.70%
자본화:
|
볼륨(24시간):